Mark J. Ratain to Antimetabolites, Antineoplastic
This is a "connection" page, showing publications Mark J. Ratain has written about Antimetabolites, Antineoplastic.
Connection Strength
1.941
-
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84.
Score: 0.369
-
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7.
Score: 0.206
-
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2002 May; 8(5):1314; author reply 1315-6.
Score: 0.190
-
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol. 2002 Mar 15; 20(6):1434-5.
Score: 0.188
-
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
Score: 0.186
-
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
Score: 0.182
-
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul; 18(14):2780-7.
Score: 0.167
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.166
-
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest. 1999; 17(7):494-506.
Score: 0.151
-
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002 Aug; 50(2):121-6.
Score: 0.048
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.037
-
Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov; 8(6):525-34.
Score: 0.032
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
Score: 0.009
-
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13.
Score: 0.008